Gabriel Garbaos

Perioperative Durvalumab for Resectable Non–Small-Cell Lung Cancer

John V. Heymach, David H. Harpole, Tetsuya Mitsudomi et al. · New England Journal of Medicine · 2023 · 682 citations · Full text

Medicine, Oncology, Perioperative Medicine +17

Abstract CT005: AEGEAN: A phase 3 trial of neoadjuvant durvalumab + chemotherapy followed by adjuvant durvalumab in patients with resectable NSCLC

John V. Heymach, David H. Harpole, Tetsuya Mitsudomi et al. · Cancer Research · 2023 · 84 citations

Medicine, Oncology, Pharmacotherapy +17

Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial

Alexander Olawaiye, Laurence Gladieff, David M. O’Malley et al. · The Lancet · 2025 · 46 citations

Medicine, Oncology, Pharmacology +13

LBA81 Final overall survival (OS) and the association of pathological outcomes with event-free survival (EFS) in MATTERHORN: A randomised, phase III study of durvalumab (D) plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric / gastroesophageal junction (G / GEJ) adenocarcinoma

J. Tabernero, S-E. Al-Batran, Zev A. Wainberg et al. · Annals of Oncology · 2025 · 10 citations

Medicine, Oncology, Pathology +9